Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | Unknown | — |
The patient missed the second dose of RabAvert, it had been three weeks since the first injection; Case reference number US-BN-2025-001463 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV25-2132) on 26-Aug-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date also reported as Day 0, the patient received the first dose of RabAvert vaccine along with its constituent parts: prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at an unknown dose, route, or site of administration, for pre-exposure prophylaxis. On an unspecified date also reported as on Day seven, the patient did not receive the second dose of RabAvert. As reported, it has been three weeks since the first injection (explicitly coded as 'incomplete course of vaccination'). At the time of initial report, it was unknown if the patient experienced any adverse events due to RabAvert. No further information was provided.; Reporter's Comments: This case concerns a male patient of unspecified age, who received the first dose of RabAvert vaccine for an indication of pre-exposure prophylaxis. The patient did not receive the second dose of RabAvert, as reported, it has been three weeks since the first injection, which is considered as 'incomplete course of vaccination'. Incomplete course of vaccination is considered as listed per company convention. At the time of initial report, it was unknown if the patient experienced any adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a male patient of unspecified age, who received the first dose of RabAvert vaccine for an indication of pre-exposure prophylaxis. The patient did not receive the second dose of RabAvert, as reported, it has been three weeks since the first injection, which is considered as 'incomplete course of vaccination'. Incomplete course of vaccination is considered as listed per company convention. At the time of initial report, it was unknown if the patient experienced any adverse events due to RabAvert. The patient's relevant medical history and concomitant medication details were not provided. Incomplete course of vaccination is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE